A study published in The Journal of Rheumatology found that febuxostat effectively reduces and maintains serum urate levels in patients with Gout, regardless of kidney function. The drug showed a ...

Am J Health Syst Pharm. 2011;68(5):389-398. As a xanthine oxidase inhibitor, febuxostat may interact with drugs that are metabolized by xanthine oxidase. Febuxostat is currently contraindicated in ...

ankle gout Researchers studied the comparative efficacy and safety of urate-lowering therapy – allopurinol vs febuxostat – in the treatment of gout. Allopurinol demonstrates noninferiority and ...

Please provide your email address to receive an email when new articles are posted on . Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy ...

In a cohort of nearly 100,000 people, researchers have found no uptick in the risk of MI, stroke, new-onset heart failure, coronary revascularization, or all-cause death for elderly patients who start ...

(UPDATED) Despite worries over a potential CV risk with febuxostat, there is indeed a population of patients with gout for whom the risk-benefit profile is favorable for the treatment of hyperuricemia ...

kidney illustration Study of patients with CKD stage 3 and asymptomatic hyperuricemia showed that febuoxostat ameliorated the annual decline in eGFR vs placebo in those without proteinuria. Febuxostat ...

Review the side-effects of Febuxostat as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Febuxostat is a novel, non-purine, selective inhibitor of xanthine oxidase for hyperuricemia in patients with gout. It is the first promising substitute for allopurinol in 40 years. Various synthetic ...

Please provide your email address to receive an email when new articles are posted on . Risk of death from all causes was similarly lower for patients on hemodialysis prescribed either allopurinol or ...

Hyperuricemia in patients with gout is most commonly treated with allopurinol. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, could potentially be a therapeutic alternative for ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impairment ...